Estrogen use should be discontinued unless its need outweighs its adverse effects on porphyrin metabolism. After achievement of remission, estrogen therapies may be cautiously reinstituted; however, the duration of remissions may be shortened. Hydroxychloroquine side effects bleeding gums Chloroquine diphosphate side effects Drug instead of hydroxychloroquine Hydroxychloroquine sweating Treatment of cutaneous porphyria depends on the specific type and the severity of the symptoms. Treatment of porphyria cutanea tarda can include Regular blood removal phlebotomies to reduce the amount of iron in the liver. Low doses of the antimalarial drug chloroquine or hydroxychloroquine. Avoidance of triggers. In the treatment of porphyria cutanea tarda, hydroxychloroquine 100 mg should be prescribed twice weekly for one month, then 200 mg/day until plasma porphyrin levels are normal for at least a month. Initial higher doses may lead to hepatotoxicity as a result of rapid mobilisation of hepatic porphyrin stores. Porphyria cutanea tarda commonly referred to as PCT is recognized as the most prevalent subtype of porphyritic diseases. The disease is characterized by onycholysis and blistering of the skin in areas that receive higher levels of exposure to sunlight. The primary cause of this disorder is a deficiency of uroporphyrinogen decarboxylase UROD, a cytosolic enzyme that is a step in the enzymatic pathway that leads to the synthesis of heme. If symptoms recur, re-treatment can restore remissions. Remissions may last from several months to many years. Why hydroxychloroquine for porphyria cutanea tarda Porphyria and its neurologic manifestations, Hydroxychloroquine DermNet NZ Chloroquine primaquine combinationWhat is plaquenil therapyHydroxychloroquine uses Arch Dermatol. 1980 Oct;116101147-50. Hydroxychloroquine treatment of porphyria cutanea tarda. Malkinson FD, Levitt L. Six patients with skin changes and urinary porphyrin excretion patterns characteristic for porphyria cutanea tarda were treated with hydroxychloroquine sulfate therapy. Hydroxychloroquine treatment of porphyria cutanea tarda.. Porphyria cutanea tarda - Wikipedia. Low-dose hydroxychloroquine is as effective as phlebotomy in treatment.. Background &AimsPorphyria cutanea tarda PCT is an iron-related disorder caused by reduced activity of hepatic uroporphyrinogen decarboxylase; it can be treated by phlebotomy or low doses of hydroxychloroquine. The treatment for Porphyria Cutanea Tarda involves a procedure called phlebotomy or by taking medication called hydroxychloroquine. Phlebotomy is a procedure in which blood is removed from the body so that the iron levels in the body becomes less which in turn helps in treatment of Porphyria Cutanea Tarda. Six patients with skin changes and urinary porphyrin excretion patterns characteristic for porphyria cutanea tarda were treated with hydroxychloroquine sulfate therapy. During treatment periods ranging from five to 13 months, cutaneous symptoms disappeared and urinary porphyrin excretion abnormalities were completely or almost completely reversed.